.
MergerLinks Header Logo

New Deal


Announced

Meridian Bioscience acquired the business of GenePOC from Debiopharm for up to $120m.

Financials

Edit Data
Transaction Value£91m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Canada

molecular diagnostics

Biotechnology

Private

Synopsis

Edit

Meridian Bioscience, a provider of diagnostic testing solutions and life science raw materials, acquired the business of GenePOC, a Quebec, Canada-based provider of molecular diagnostic instruments and assays, from Debiopharm for up to $120m. Jack Kenny, Chief Executive Officer, commented: “This is a critical element of our strategy to re-position our Diagnostics business for sustainable long-term growth. GenePOC’s revogeneTM platform is an excellent fit for our customers and strategy to offer gastrointestinal-focused and other targeted diagnostic solutions to meet the diverse needs of today’s more complex health care system. We welcome the GenePOC team to the Meridian family and look forward to leveraging Meridian’s strong and established commercial infrastructure to offer revogeneTM and its menu of assays to our current and new customers.”

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US